Selank is a Russian psychotropic with no Western evidence

This objection is half right, and the half it gets wrong matters. The half it gets right: the gold-standard FDA-grade evidence Western prescribers expect for an anxiolytic — large multi-center placebo-controlled trials with prespecified primary endpoints, regulatory-quality methodology, independent replication across unaffiliated research groups — does not exist for Selank. Anyone reading "approved in Russia since 2009 for generalized anxiety disorder and neurasthenia" and assuming the same level of evidence supports it as supports an SSRI is going to be disappointed when they look at the underlying papers. The phrase *evidence-depth gap* is not a softening — it is the central honest fact about Selank. The half it gets wrong: the Russian clinical literature is not absence-of-evidence. It is *parallel* evidence. The active-comparator trial of Selank versus medazepam (a benzodiazepine) in 62 patients with GAD or neurasthenia (Zozulya et al., *Zh Nevrol Psikhiatr* 2008) reports clinically comparable anxiolytic effects with additional antiasthenic and mild psychostimulant activity for Selank. Russian neuropharmacology research over three decades has produced dozens of clinical and mechanistic publications, several of which appear in PubMed via translated abstracts. Western mechanistic work — for example Filatova et al., *Frontiers in Pharmacology* 2017, on Selank's modulation of GABA-induced gene expression in IMR-32 cells, and Bulletin of Experimental Biology and Medicine 2019 on BDNF effects in rat hippocampus — corroborates the proposed mechanism even if it does not by itself establish clinical efficacy. The right characterization is two evidence bases that have not yet converged. Russian regulatory science approved Selank against domestic methodological standards. Western regulatory science (FDA, EMA) has not been asked, has not run independent trials, and does not have a verdict either way. "No Western evidence" overstates the case; "no Western *clinical-trial* replication of the Russian efficacy claims" is accurate. Those are different sentences. Where the critic has a real point: anyone considering Selank as a substitute for an SSRI or benzodiazepine in a clinical context where regulatory-grade evidence is the decision standard is acting on the Russian literature alone, and that is a meaningful step beyond what an evidence-based prescriber would do for the more rigorously studied alternatives. The non-sedating profile is mechanistically plausible and clinically reported, but the magnitude of effect and the long-tail safety in Western populations are not characterized. Where the critic loses the thread: dismissing three decades of clinical use plus the published mechanistic work as "no Western evidence" treats the bar for what counts as evidence as binary — peer-reviewed by the FDA-acceptable gauntlet or it does not exist — and that bar is not how evidence actually works. The Russian literature is real, the methodological standards are imperfect by Western lights, and the right read is "thin Western validation, parallel domestic record" rather than "fabrication."